Healthcare

Health Check: Brokers Reduce Cochlear Valuations as Customers Delay...

Biotech Industry Update: Key Developments and Trials

Recce Pharmaceuticals Advances in Fight Against Skin Infections with...

Highlights:,Positive results from Phase II trial of Recce 327 topical gel,No serious adverse events reported, meeting all safety and efficacy endpoint...

ASX Closes Lower as (ASX:AD8) Surges 26% and (ASX:BEN) Faces Sharp D...

Highlights,(ASX:AD8) jumps 26% after strong half-year results,(,ASX:BEN,) slides 15% on weaker margins and earnings shortfall,Seven sectors end in the...

Sonic Healthcare (ASX:SHL): A Closer Look at Stock Performance and L...

Highlights,Sonic Healthcare (SHL) sees a 10% rise in,quarterly,share price.,Shareholder,return over the past three years shows a 23% decline.,Dividend...

Recce Pharmaceuticals Shows Promising Results for Topical Gel in Tre...

Highlights,Recce Pharmaceuticals’ Phase II clinical trial of its topical gel, RECCE 327 (R327G), achieved a 93% primary efficacy endpoint in treating...

Recce Pharmaceuticals (ASX:RCE) Advances R327G to Phase III After Po...

Highlights:,93% Efficacy Rate:,Recce Pharmaceuticals (ASX:RCE) reported that R327G achieved a 93% primary efficacy endpoint in its Phase II trial for...

Althea Group’s Expansion into the North American THC Beverage Market

Cannabis in a Can: Nanocap Althea Secures $4M to Boost THC Beverage Expansion in the US and Canada

Recce Pharmaceuticals (ASX:RCE) Advances ABSSSI Treatment with Posit...

Breakthrough in Infection Treatment: Recce Pharmaceuticals (ASX:RCE) Reports Strong Clinical Results

Health Check: After treating its final patient, Opthea anticipates t...

Biotech Developments and Market Movements in Focus

Imugene is well-funded and on the brink of revolutionizing cancer im...

Highlights:,Imugene is advancing three immunotherapy programs focused on CAR-T therapies and oncolytic viruses.,The company secured new funding throug...

Will ASX:ARX Reinvent Its Course in a Rapidly Expanding Sector?

Highlights,ASX:ARX experienced a sharp decline in share price, erasing earlier gains.,The company’s price-to-sales ratio remains much lower compared t...

CSL's Earnings for the First Half of 2025: EPS Falls Short of Expect...

Highlights:,CSL Limited (ASX:CSL) reported an increase in revenue in its latest financial results.,Earnings per share came in below expectations despi...

Can Imagion Biosystems Transform HER2 Imaging for Cancer Diagnostics...

Highlights,• MagSense HER2 imaging agent manufacturing commences for advanced clinical trials.,• Innovative imaging technology aims to enhance cancer...

What Key Developments Define ASX:PME in Healthcare Imaging?

Highlights,Earnings per share growth has been robust.,Company leaders own a considerable portion of stock.,Governance practices and CEO compensation r...

Avita Medical (ASX:AVH) Surges Over 11% on Strong Growth Outlook

Highlights,Avita Medical (AVH) shares,jump,over 11% following,revenue,guidance announcement.,Company,projects a 55-65% growth in,full-year,2024 commer...

Healius Surges Amid Fresh Merger Talks with Australian Clinical Labs

Highlights,Healius,(,ASX:HLS,),emerges,as the top performer on the ASX 200 after reports of renewed merger discussions.,Australian Clinical Labs (ASX:...

Pro Medicus Gains Momentum as Analysts Raise Price Target

Highlights,Pro Medicus (PME) receives an upgraded outlook with a higher price target.,Shares recover after a dip following,first,-half earnings result...

Imugene's (ASX:IMU) Azer-cel Trial Shows Strong 57% Complete Respons...

Highlights,Promising Trial Data:,Azer-cel achieves a,57% complete response rate,in relapsed lymphoma patients.,Enhanced Immune Response:,The addition...

Sonic Healthcare and Brambles: Stocks to Watch for Growth and Stabil...

Highlights,(SHL),has seen a 9.4% dip in 2024 but,remains,a key player in global pathology services.,(BXB),is near its 52-week high,,benefiting,from it...

AVITA Medical Soars 10% on Revenue Growth and Optimistic Outlook

Highlights,Revenue Surge:,AVITA Medical reports a 30% increase in Q4 commercial revenue, reaching US$18.4 million, with full-year revenue up 29% to US...